Results 11 to 20 of about 45,216 (237)

Increased CAPG inhibits ferroptosis to drive tumor proliferation and sorafenib resistance in hepatocellular carcinoma via the WDR74-p53-SLC7A11 pathway. [PDF]

Int J Biol Sci
Quan B, Yao F, Liu W, Tang B, Li M, Lu S, Li J, Chen R, Ren Z, Yin X.   +9 more
europepmc   +3 more sources

MYB Confers Sorafenib Resistance in Human Leukemia Cells via Inhibiting Ferroptosis Through FTH1 Upregulation. [PDF]

Genes (Basel)
Tao X, Wang Y, Shen S, Fang H, Song H, Zhang J, Han B.   +6 more
europepmc   +3 more sources

Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation. [PDF]

Front Pharmacol
Zhou Q, Wang R.
europepmc   +3 more sources

Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance

Cells, 2022
Sorafenib is a small molecule that blocks tumor proliferation by targeting the activity of multi-kinases for the treatment of advanced hepatocellular carcinoma (HCC). Increasing sorafenib resistance following long-term treatment is frequently encountered.
Yung-Sheng Chang, Chien-Wei Su, San-Chi Chen, Yen-Ying Chen, Yuh-Jin Liang, Jaw-Ching Wu   +5 more
doaj   +1 more source

Combined downregulation of TGF-β1 and GRP78 is responsible for overcoming acquired sorafenib resistance, which is initiated by rewiring the cell surface CD44-GRP78-IGF-1R signaling circuit. [PDF]

Cancer Gene Ther
Li S, Oh GH, Hong JA, Choi S, Kim M, Kwon H, Ko SK, Park SJ, Kim HK, Choi HJ, Song JJ.   +10 more
europepmc   +3 more sources

cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence: Erratum [PDF]

Int J Biol Sci
Ruan Y, Chen T, Zheng L, Cai J, Zhao H, Wang Y, Tao L, Xu J, Ji L, Cai X.   +9 more
europepmc   +3 more sources

Endoplasmic Reticulum Membrane Protein Complex Regulates Cancer Stem Cells and is Associated with Sorafenib Resistance in Hepatocellular Carcinoma. [PDF]

J Hepatocell Carcinoma
Liu YJ, Li JX, Li JP, Hu YD, Ma ZB, Huang W, Liu SL, Zou X.   +7 more
europepmc   +2 more sources

The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma

Frontiers in Oncology, 2021
BackgroundSorafenib is the first molecular-targeted drug for the treatment of advanced hepatocellular carcinoma (HCC). However, its treatment efficiency decreases after a short period of time because of the development of drug resistance.
Yi Shi, Yi Shi, Xiaojiang Wang, Xiaojiang Wang, Qiong Zhu, Gang Chen, Gang Chen   +6 more
doaj   +1 more source

Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research, 2022
Background Hepatocellular carcinoma (HCC) is one of the most malignant tumors and the fourth leading cause of cancer-related death worldwide. Sorafenib is currently acknowledged as a standard therapy for advanced HCC.
Danyang Li, Yingcheng Yao, Yuhan Rao, Xinyu Huang, Li Wei, Zhimei You, Guo Zheng, Xiaoli Hou, Yu Su, Zac Varghese, John F. Moorhead, Yaxi Chen, Xiong Z. Ruan   +12 more
doaj   +1 more source

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis

Journal of Experimental & Clinical Cancer Research, 2023
Background Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore
Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng, Chuanyong Guo   +13 more
doaj   +1 more source